Adalimumab for the treatment of Crohn’s disease
Andrea Cassinotti, Sandro Ardizzone, Gabriele Bianchi PorroDepartment of Clinical Sciences, Chair of Gastroenterology, “Luigi Sacco” University Hospital, Milan, ItalyIntroduction: Crohn’s disease (CD) is a chronic inflammatory bowel disease characterized by...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1eb50cbe23e1438183d461c303f6e725 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:1eb50cbe23e1438183d461c303f6e725 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:1eb50cbe23e1438183d461c303f6e7252021-12-02T08:19:26ZAdalimumab for the treatment of Crohn’s disease1177-54751177-5491https://doaj.org/article/1eb50cbe23e1438183d461c303f6e7252008-09-01T00:00:00Zhttp://www.dovepress.com/adalimumab-for-the-treatment-of-crohnrsquos-disease-a2232https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Andrea Cassinotti, Sandro Ardizzone, Gabriele Bianchi PorroDepartment of Clinical Sciences, Chair of Gastroenterology, “Luigi Sacco” University Hospital, Milan, ItalyIntroduction: Crohn’s disease (CD) is a chronic inflammatory bowel disease characterized by a relapsing-remitting course with trans-mural inflammation of potentially any section of the digestive tract. Adalimumab (ADA) is a subcutaneously administered, recombinant, fully human, IgG1 monoclonal antibody that binds with high affinity and specificity to human TNF-alpha, thus modulating its biologic functions and its proinflammatory effects.Aims: To review the available data on ADA in CD for biological properties, efficacy, and safety.Methods: Electronic searches were conducted using the Pubmed and SCOPUS databases from the earliest records to April 2008. The search terms used were “adalimumab”, “anti-TNF”, “TNF-alpha”, “biologicals”, “inflammatory bowel disease”, and “Crohn’s disease”. Reference lists of all relevant articles were searched for further studies.Results: Available studies suggest that ADA has the potential to induce and maintain clinical response and remission in moderate-severe CD, both in anti-TNF-naïve patients and in subjects who lost their response and/or became intolerant to infliximab (IFX). ADA seems also effective in maintaining corticosteroid-free remission and obtaining complete fistula closure (although no specific randomized trials are available). No concomitant immunosuppressors seem to be necessary. Side effects appear similar to IFX, while site-injection reactions are frequent and specific. Data on immunogenicity and its clinical impact are uncertain.Conclusions: ADA appears to be effective in inducing and maintain clinical remission in CD, including patients not manageable with IFX. Successive clinical practice and further on going trials will confirm a positive role for ADA as a new anti-TNF treatment in CD. The impact on clinical management or on resources should be more studied.Keywords: Crohn’s disease, adalimumab, anti-TNF, treatment, biologics Andrea CassinottiSandro ArdizzoneGabriele Bianchi PorroDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 4, Pp 763-777 (2008) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Andrea Cassinotti Sandro Ardizzone Gabriele Bianchi Porro Adalimumab for the treatment of Crohn’s disease |
| description |
Andrea Cassinotti, Sandro Ardizzone, Gabriele Bianchi PorroDepartment of Clinical Sciences, Chair of Gastroenterology, “Luigi Sacco” University Hospital, Milan, ItalyIntroduction: Crohn’s disease (CD) is a chronic inflammatory bowel disease characterized by a relapsing-remitting course with trans-mural inflammation of potentially any section of the digestive tract. Adalimumab (ADA) is a subcutaneously administered, recombinant, fully human, IgG1 monoclonal antibody that binds with high affinity and specificity to human TNF-alpha, thus modulating its biologic functions and its proinflammatory effects.Aims: To review the available data on ADA in CD for biological properties, efficacy, and safety.Methods: Electronic searches were conducted using the Pubmed and SCOPUS databases from the earliest records to April 2008. The search terms used were “adalimumab”, “anti-TNF”, “TNF-alpha”, “biologicals”, “inflammatory bowel disease”, and “Crohn’s disease”. Reference lists of all relevant articles were searched for further studies.Results: Available studies suggest that ADA has the potential to induce and maintain clinical response and remission in moderate-severe CD, both in anti-TNF-naïve patients and in subjects who lost their response and/or became intolerant to infliximab (IFX). ADA seems also effective in maintaining corticosteroid-free remission and obtaining complete fistula closure (although no specific randomized trials are available). No concomitant immunosuppressors seem to be necessary. Side effects appear similar to IFX, while site-injection reactions are frequent and specific. Data on immunogenicity and its clinical impact are uncertain.Conclusions: ADA appears to be effective in inducing and maintain clinical remission in CD, including patients not manageable with IFX. Successive clinical practice and further on going trials will confirm a positive role for ADA as a new anti-TNF treatment in CD. The impact on clinical management or on resources should be more studied.Keywords: Crohn’s disease, adalimumab, anti-TNF, treatment, biologics |
| format |
article |
| author |
Andrea Cassinotti Sandro Ardizzone Gabriele Bianchi Porro |
| author_facet |
Andrea Cassinotti Sandro Ardizzone Gabriele Bianchi Porro |
| author_sort |
Andrea Cassinotti |
| title |
Adalimumab for the treatment of Crohn’s disease |
| title_short |
Adalimumab for the treatment of Crohn’s disease |
| title_full |
Adalimumab for the treatment of Crohn’s disease |
| title_fullStr |
Adalimumab for the treatment of Crohn’s disease |
| title_full_unstemmed |
Adalimumab for the treatment of Crohn’s disease |
| title_sort |
adalimumab for the treatment of crohn’s disease |
| publisher |
Dove Medical Press |
| publishDate |
2008 |
| url |
https://doaj.org/article/1eb50cbe23e1438183d461c303f6e725 |
| work_keys_str_mv |
AT andreacassinotti adalimumabforthetreatmentofcrohnamprsquosdisease AT sandroardizzone adalimumabforthetreatmentofcrohnamprsquosdisease AT gabrielebianchiporro adalimumabforthetreatmentofcrohnamprsquosdisease |
| _version_ |
1718398531930161152 |